The Lancet thelancet.com

[Comment] Immediate or staged complete revascularisation in patients with ST segment elevation myocardial infarction

thelancet.com·37w

[Articles] Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a mult...

thelancet.com·37w

[Articles] Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a...

thelancet.com·37w

[Comment] Paclitaxel in the lower limbs: harm outweighs the benefit

thelancet.com·37w

[Comment] The ICJ Advisory Opinion: a legal mandate for planetary health

thelancet.com·37w

[Series] Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention

thelancet.com·37w

[Series] Prevention of heart failure after acute myocardial infarction

thelancet.com·37w

[Articles] Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 tri...

thelancet.com·37w

[Comment] Good governance essential to expanding vaccine capacity and strengthening public trust

thelancet.com·37w

[Articles] Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-random...

thelancet.com·37w

[Comment] Vericiguat across the heart failure spectrum

thelancet.com·37w

[Articles] β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trial...

thelancet.com·37w

[Comment] Influenza vaccination in heart failure: a shot worth taking?

thelancet.com·37w

[Articles] Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-random...

thelancet.com·38w

[Comment] Influenza vaccination in heart failure: a shot worth taking?

thelancet.com·38w

[Articles] β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trial...

thelancet.com·38w

[Articles] Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 tri...

thelancet.com·38w

[Articles] Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VIC...

thelancet.com·38w

[Comment] Vericiguat across the heart failure spectrum

thelancet.com·38w

[Series] Prioritising the primary prevention of heart failure

thelancet.com·38w

Log in to enable infinite scrolling